PCDHB9: A Non-Coding RNA Molecule Regulating Gene Expression (G56127)

Target Name: PCDHB9

NCBI ID: G56127

PCDHB9

PCDHB9: A Non-Coding RNA Molecule Regulating Gene Expression

PCDHB9 (PCDH3H), also known as GABA-ZAP, is a non-coding RNA molecule that plays a critical role in the regulation of gene expression. It is a highly conserved gene that is expressed in many different tissues and cells, including brain, spinal cord, and heart.

PCDHB9 is a RNA-protein hybrid that consists of a 193-nt cDNA fragment and a 21-nt protein fragment. The protein fragment contains a unique N-terminal region that is rich in conserved secondary structure elements, such as a leucine- rich repeat (LRR), a proline-rich repeat (PRR), and a phenylalanine-rich repeat (PAR). These conserved elements are important for protein stability and functions, such as protein-protein interactions and localization to specific cellular compartments.

PCDHB9 is a negative regulator of gene expression, which means that when a gene is expressed, PCDHB9 will prevent it from being translated into protein. This is accomplished by binding to specific mRNAs and preventing their translation into proteins. This process is regulated by multiple factors , including the translation machinery, RNA binding proteins (RBP), and microRNA (miRNA) systems.

PCDHB9 has been shown to play a role in the regulation of a wide range of cellular processes, including neuronal development, synaptic plasticity, and stress response. It has been shown to be involved in the development and progression of several neurological disorders, such as Alzheimer's disease, Parkinson's disease, and epilepsy.

In addition to its role in neurological disorders, PCDHB9 has also been shown to be involved in a variety of other cellular processes, including cell signaling, cell adhesion, and cell migration. It has been shown to play a role in the regulation of cell proliferation. , cell differentiation, and cell survival.

PCDHB9 is also a potential drug target in the treatment of various neurological disorders. For example, studies have shown that inhibiting PCDHB9 can improve neurogenic rescue in patients with Alzheimer's disease and that this may be a promising strategy for the treatment of this disease. Additionally, PCDHB9 has been shown to be involved in the regulation of pain perception and neuroinflammation, which may make it a potential target for the treatment of chronic pain and neuroinflammation.

In conclusion, PCDHB9 is a non-coding RNA molecule that plays a critical role in the regulation of gene expression and has been shown to be involved in a wide range of cellular processes. Its unique conserved N-terminal region and its role as a negative regulator of gene expression make it a promising target for the development of new therapies for a variety of neurological disorders. Further research is needed to fully understand the mechanisms of PCDHB9's role in gene regulation and its potential as a drug target.

Protein Name: Protocadherin Beta 9

Functions: Potential calcium-dependent cell-adhesion protein. May be involved in the establishment and maintenance of specific neuronal connections in the brain

The "PCDHB9 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PCDHB9 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets